Healx Begins Phase 2 Trial Dosing for HLX-1502 in Neurofibromatosis Type 1
Healx Begins Phase 2 Trial Dosing for HLX-1502 in Neurofibromatosis Type 1 Healx, an AI-driven, clinical-stage biotechnology company focused on developing treatments for rare diseases, has announced a major milestone…
Glaukos Receives FDA Acceptance for Epioxa™ NDA Submission
Glaukos Receives FDA Acceptance for Epioxa™ NDA Submission Glaukos Corporation (NYSE: GKOS), a leading ophthalmic pharmaceutical and medical technology company specializing in innovative therapies for the treatment of glaucoma, corneal…
Bruker Expands Proteomics Capabilities with New Software at US HUPO
Bruker Expands Proteomics Capabilities with New Software at US HUPO At the 21st Annual US HUPO Conference, Bruker Corporation (Nasdaq: BRKR) announced significant advancements in 4D-Proteomics™ performance, software, and applications…
Halda Therapeutics Doses First Patient in HLD-0915 Phase 1/2 Trial for mCRPC
Halda Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of HLD-0915 for Metastatic Castration-Resistant Prostate Cancer Halda Therapeutics, a clinical-stage biotechnology company focused on developing a novel class of…
Synnovation Therapeutics Doses First Patient in Phase I Trial for PI3Kα Inhibitor SNV4818
Synnovation Therapeutics Doses First Patient in Phase I Trial for PI3Kα Inhibitor SNV4818 Synnovation Therapeutics Initiates Phase I Trial for SNV4818: A Potential Best-in-Class Pan-Mutant-Selective PI3Kα Inhibitor Introduction Synnovation Therapeutics,…
AN2 Shares Strategic Update on Phase 3 EBO-301 Trial for Treatment-Refractory MAC Lung Disease
AN2 Therapeutics Announces Strategic Update on Phase 3 EBO-301 Trial for Treatment-Refractory MAC Lung Disease AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company dedicated to discovering and developing innovative small-molecule…
Latus Bio Presents Preclinical Data Supporting Its Huntington’s Disease Gene Therapy Program
Latus Bio Presents Preclinical Data Supporting Its Huntington’s Disease Gene Therapy Program Latus Bio, Inc. (Latus), a biotechnology company pioneering advancements in adeno-associated virus (AAV) gene therapy, is pleased to…
FDA Accepts sBLA for Opdivo® + Yervoy® in MSI-High/dMMR Cancers
FDA Accepts sBLA for Opdivo® + Yervoy® in MSI-High/dMMR Cancers U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with…
Revelation Biosciences, Inc. Secures Ongoing NASDAQ Listing Approval
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company dedicated to developing novel therapies aimed at rebalancing inflammation to optimize health, announced today that the…
Samsung Bioepis Launches PYZCHIVA® (ustekinumab-ttwe) Biosimilar to Stelara in the U.S.
Samsung Bioepis Co., Ltd. has announced the official U.S. launch of PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), expanding treatment options for patients with inflammatory conditions. This development marks a…
Estrella Immunopharma Advances STARLIGHT-1 Trial to Higher Dose Cohort
Estrella Immunopharma Advances STARLIGHT-1 Trial to Higher Dose Cohort Following Successful Initial Results Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company focused on developing…
Seaport Therapeutics Analyzes Trial Design and Placebo Response in MDD
Seaport Therapeutics Investigates Clinical Trial Design and Placebo Response in Major Depressive Disorder Studies Seaport Therapeutics (“Seaport” or “the Company”), a clinical-stage biopharmaceutical company focused on advancing innovative neuropsychiatric medicines,…